Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Data Reporting and Recording01:24

Data Reporting and Recording

Reporting and recording are crucial in data documentation. The timely, thorough, and accurate documentation of facts is essential when recording patient data. Failure to record findings during an assessment or interpretation of a problem will result in loss of information and make the patient document unreliable. The reader is left with general impressions if the information is not specific. A recording is documenting data of the individual's health information in a traceable, secure, and...
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
Purpose of Health Records II01:19

Purpose of Health Records II

Health records serve various essential purposes in the healthcare system. Here are some key purposes:
Data Collection I01:30

Data Collection I

Data collection gathers information needed to make accurate judgments about a patient's present condition. During a health history interview, subjective data is collected from the patient, their caregivers, or family members, and objective data is collected through observations and physical assessment. Patients are the primary source of subjective data. Thus information gathered from patients through interviews, observations, and physical examination is primary data. Secondary sources of data...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacists in obstetrics.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2018
Same author

Should pregnant women be included in phase IV clinical drug trials?

American journal of obstetrics and gynecology·2015
Same author

The pharmacologic management of nausea and vomiting of pregnancy.

The Journal of family practice·2014
Same author

Obstetrical opportunities: will pharmacy ever realize them?

The Annals of pharmacotherapy·2012
Same author

Use of duloxetine in pregnancy and lactation.

The Annals of pharmacotherapy·2009
Same author

High-dose carisoprodol during pregnancy and lactation.

The Annals of pharmacotherapy·2008
Same journal

Corrigendum for: Levels of folate receptor autoantibodies in maternal and cord blood and risk of neural tube defects in a Chinese population, 106:685-695 (10.1002/bdra.23517).

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Response to Dr. Kirby.

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Response to letter to the editor by Wise.

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Letter to the editor: Comments on venlafaxine paper by Laurent et al.

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011.

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Evaluation of the Western Australian Register of Developmental Anomalies: Thirty-five years of surveillance.

Birth defects research. Part A, Clinical and molecular teratology·2016
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
12:17

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

Better data needed from pregnancy registries.

Gerald G Briggs1, Janine Polifka,

  • 1Perinatal Support Service, MemorialCare Center for Women, Miller Children's Hospital, Long Beach Memorial Medical Center, Long Beach, CA 90806, USA. jbriggs@memorialcare.org

Birth Defects Research. Part A, Clinical and Molecular Teratology
|December 25, 2008
PubMed
Summary
This summary is machine-generated.

Improving pregnancy registries requires precise drug exposure data. Specific timing in gestational weeks and days, and patient-specific doses (mg/kg or mg/m²) enhance developmental toxicity risk assessment.

Related Experiment Videos

Last Updated: Jun 26, 2026

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
12:17

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo

Published on: August 2, 2017

Area of Science:

  • Reproductive toxicology
  • Pharmacoepidemiology
  • Developmental biology

Background:

  • Pregnancy registries are crucial for assessing medication safety during gestation.
  • Current data collection methods may lack the specificity needed for accurate risk evaluation.
  • Accurate exposure data is vital for understanding medication effects on fetal development.

Purpose of the Study:

  • To advocate for enhanced data collection standards in pregnancy registries.
  • To improve the precision of developmental toxicity risk estimation.
  • To provide recommendations for reporting drug exposure timing and dosage.

Main Methods:

  • Consensus position statement development by the Organization of Teratology Information Specialists (OTIS) Research Committee.
  • Analysis of existing data reporting practices in pregnancy registries.
  • Formulation of specific recommendations for exposure data parameters.

Main Results:

  • Current pregnancy registry data often lacks specific exposure timing (gestational weeks and days) and patient-specific dosage information (e.g., mg/kg, mg/m²).
  • Increased specificity in reporting exposure timing and dose is believed to significantly improve risk estimation for developmental toxicity.
  • These recommendations are applicable beyond pharmaceutical-sponsored registries to all sources of medication-induced embryo-fetal toxicity data.

Conclusions:

  • Standardizing the reporting of gestational timing and patient-specific dosage in pregnancy registries is essential.
  • Enhanced data specificity will lead to more accurate assessments of developmental toxicity risks associated with drug exposure.
  • The proposed standards aim to improve the safety evaluation of medications used during pregnancy.